Actionable news
All posts from Actionable news
Actionable news in GILD: Gilead Sciences, Inc.,

Gilead Says Two Phase 3 Trials On Tenofovir Alafenamide Met Primary Objectives

Shutterstock photo

( - Gilead Sciences, Inc. (

) announced that two Phase 3 clinical trials, Studies 108 and 110, regarding investigational use of once-daily tenofovir alafenamide (TAF) 25 mg in treatment-naïve and treatment-experienced adults with HBeAg-negative and...